Dhédin, Nathalie
https://orcid.org/0009-0003-3085-6539
Mayo Clinic
Assistance Publique – Hôpitaux de Paris
Citations 1
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma
Merryman, Reid W. , Zinzani, Pier Luigi , Carlo‐Stella, Carmelo , Ansell, Stephen M. , Perales, Miguel-Angel, Avigdor, Abraham, Halwani, Ahmad , Houot, Roch, Marchand, Tony , Dhédin, Nathalie , Lescaut, W., Thiebaut‐Bertrand, Anne , François, Sylvie, Stamatoullas‐Bastard, Aspasia, Rohrlich, Pierre-Simon, Wallet, Hélène Labussière, Castagna, Luca , Santoro, Armando , Bachanová, Veronika , Bresler, Scott C., Kim, Harim , Pesek, Emily, Chammas, Marie J, Reynolds, Carol, Ho, Vincent T., Antin, Joseph H., Soiffer, Robert J. , Armand, Philippe , Kim, Haesook T. , Houot, Roch , Rohrlich, Pierre‐Simon , Bresler, Scott C. , Srivastava, Amitabh , Reynolds, Carol, Antin, Joseph H. , Ritz, Jerome , Bachanova, Veronika , Zinzani, Pier Luigi , Santoro, Armando , Castagna, Luca , Carlo-Stella, Carmelo , Merryman, Reid W
Blood | January 10, 2017 | Volume: 129 | Issue: 10 | Pages: 1380-1388
Key Points HSCT after PD-1 blockade is feasible, although may be associated with increased early immune toxicity. PD-1 blockade may cause persistent depletion of PD1+ T cells and alterations in T-cell differentiation impacting subsequent treatment.